Comparison of Efficacy of Labetalol Versus Alpha Methyldopa in the Management of Preeclampsia
DOI:
https://doi.org/10.70749/ijbr.v3i4.2878Keywords:
Antihypertensive Agents; Hypertension, Pregnancy-Induced; Labetalol; Methyldopa; Pre-EclampsiaAbstract
Background: Preeclampsia is a hypertensive disorder that occurs after 20 weeks of gestation and is known to be one of the major causes of morbidity for mothers and their fetuses. The regulation of blood pressure is important in order to prevent severe consequences for mothers and their fetuses. Objective: To compare the efficacy of labetalol and alpha methyldopa in management of preeclampsia. Study Design: Randomized controlled trial. Duration and Place of Study: This study was conducted from 10 April 2024 to 10 October 2024 in Department of Obstetrics and Gynaecology, Zanana Hospital, Dera Ismail Khan. Methodology: A total of 190 women aged 18 to 40 years with singleton pregnancy more than 30 weeks and diagnosed preeclampsia were included. Patients were randomly divided into two equal groups. Group A received labetalol 100 milligram twice daily and Group B received alpha methyldopa 250 milligram three times daily. Efficacy was defined as blood pressure less than 140/90 millimeter of mercury within 48 hours without dose escalation. Data were analyzed using Statistical Package for Social Sciences version 26. Results: Mean age was 29.03 ± 6.36 years in labetalol group and 29.37 ± 7.32 years in alpha methyldopa group. Efficacy was achieved in 81 (85.3%) patients receiving labetalol and 67 (70.5%) receiving alpha methyldopa, showing significant difference (p = 0.014). Conclusion: Labetalol was more effective than alpha methyldopa for controlling blood pressure in preeclampsia.
Downloads
References
1. Stanhewicz AE, Wenner MM, Stachenfeld NS. Sex differences in endothelial function: implications for pregnancy and preeclampsia. Clin Sci (Lond). 2021;135(11):1347-1367.
https://doi.org/10.1042/CS20200862
2. Najeeb MN, Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ, Batiha GE. The role of adropin in preeclampsia: a systematic review. Medicina (Kaunas). 2024;60(8):1324.
https://doi.org/10.3390/medicina60081324
3. Wali K, Shaukat MS, Khan J, Martinez A, Gorthi S, Ehikioya E, et al. Preeclampsia: a comprehensive review of its pathophysiology, diagnosis, and management. Cureus. 2024;16(8):e67768. https://doi.org/10.7759/cureus.67768
4. Owaraganise A, Mukunya D, Ngonzi J, Mbalinda SN, Nakimuli A, Kaye DK, et al. Proteinuria among women with preeclampsia and its association with adverse maternal and fetal outcomes at Mbarara Regional Referral Hospital, Southwestern Uganda. Obstet Gynecol Int. 2021; 2021(1):1473210.
https://doi.org/10.1155/2021/1473210
5. Al Fahdi M, Al-Rasadi K, Al-Kindi M, Al-Busaidi IS, Al-Maqbali NS, Al-Sinani S, et al. Maternal and neonatal outcomes of preeclampsia in a tertiary hospital in Oman: a retrospective study. BMC Womens Health. 2024;24(1):640.
https://doi.org/10.1186/s12905-024-03487-y
6. Cífková R. Treatment of hypertension in pregnancy. High Blood Press Cardiovasc Prev. 2023;30(5):401-411.
https://doi.org/10.1007/s40292-023-00595-5
7. Martinez A, Gorthi S, Shaukat MS, Ehikioya E, Khan J, Wali K, et al. Management of preeclampsia: a comprehensive review. Cureus. 2023;15(8):e44464.
https://doi.org/10.7759/cureus.44464
8. Ehikioya E, Shaukat MS, Gorthi S, Martinez A, Khan J, Wali K, et al. Antihypertensive therapy in preeclampsia: a review of current evidence. Cureus. 2023;15(7):e42436.
https://doi.org/10.7759/cureus.42436
9. Tropea T, Mavichak W, Evangelinos A, Mol BW, Ganzevoort W, O’Brien P, et al. Fetoplacental vascular effects of maternal adrenergic antihypertensive and cardioprotective medications in pregnancy. J Hypertens. 2023;41(11):1675-1687.
https://doi.org/10.1097/HJH.000000000003532
10. Gupta M, Al Khalili Y. Methyldopa. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
https://www.ncbi.nlm.nih.gov/books/NBK551671/
11. Allehyani RF, Alsehli AA, Saggat RZ, Aldurdunji MM, Alorfi NM. Pharmacological treatment of pregnancy complications in adults: an overview of phase IV clinical trials. Medicine (Baltimore). 2025;104(5):e41322.
https://doi.org/10.1097/MD.0000000000041322
12. Mah GT, Tejani AM, Musini VM. Methyldopa for primary hypertension. Cochrane Database Syst Rev. 2009;2009(4):CD003893. https://doi.org/10.1002/14651858.CD003893.pub3
13. Conti-Ramsden F, de Marvao A, Chappell LC. Pharmacotherapeutic options for the treatment of hypertension in pregnancy. Expert Opin Pharmacother. 2024;25(13):1739-1758. https://doi.org/10.1080/14656566.2024.2398602
14. Preethi B, Sindhuja B. Comparison of efficacy of labetalol versus alpha-methyldopa in the management of preeclampsia. Int J Sci Stud. 2021;9(4):121-124.
15. Khalid H, Parveen F, Begum A, Ismail A, Detho S, Khalid U. Efficacy of labetalol versus methyldopa in pregnancy induced hypertension among patients visiting tertiary care hospital. J Soc Obstet Gynaecol Pak. 2021;11(2):131-134.
16. Qazi VH, Iqbal J, Aman M, Kousar Y. Efficacy of methyldopa versus labetalol in the treatment of pregnancy induced hypertension: a randomized control. Int J Sci Res. 2019;8(8).
17. Arshad M, Farooq S, Majeed K, Khalid U, Afsheen A, Artemis P. Labetalol versus methyldopa for treatment of pregnancy induced hypertension. Pak Armed Forces Med J. 2024;74(4):1024-1027.
18. Kumari R, Raman RK, Kumari U. Comparison of therapeutic effects of labetalol with other anti-hypertensives in control of hypertension in pregnancy induced hypertension in a tertiary care hospital. Int J Acad Med Pharm. 2023;5(5):1230-1234.
19. Saad S, Kumari R, Kumud M, Kumar S. Comparative study of labetalol and methyldopa in treatment of pregnancy induced hypertension. Int J Curr Pharm Rev Res. 2025;17(1):605-610.
20. Jayanthy T, Kirana T, Nirmala S. A comparative study of labetalol versus methyldopa in the treatment of preeclampsia. J Evid Based Med Healthc. 2016;3(8):243-244.
21. Biswas C, Biswas B. Comparative study of efficacy of methyldopa vs labetalol in the management of pregnancy induced hypertension in respect to maternal and perinatal outcome. Int J Clin Obstet Gynaecol. 2021;5(6):258-264.
https://doi.org/10.33545/gynae.2021.v5.i6d.1092
22. Khan ZA, Sabah S, Sheikh JS, Ubaid R, Shah R, Karim Z. Efficacy and safety of methyldopa and labetalol in the treatment of pre-eclampsia. Pak J Med Health Sci. 2023;17(12):115-118.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
